Cerity Partners LLC Grows Stake in Medpace Holdings, Inc. $MEDP

Posted by Brenda Bartman on Jun 11th, 2026

Cerity Partners LLC raised its stake in Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 41.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 80,973 shares of the company’s stock after acquiring an additional 23,530 shares during the quarter. Cerity Partners LLC’s holdings in Medpace were worth $45,478,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in MEDP. Optiver Holding B.V. purchased a new position in Medpace in the third quarter valued at about $27,000. Geneos Wealth Management Inc. lifted its stake in shares of Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after buying an additional 37 shares in the last quarter. Steigerwald Gordon & Koch Inc. purchased a new stake in shares of Medpace during the 4th quarter valued at approximately $30,000. Elyxium Wealth LLC purchased a new stake in shares of Medpace during the 4th quarter valued at approximately $30,000. Finally, Quarry LP purchased a new stake in shares of Medpace during the 3rd quarter valued at approximately $35,000. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Medpace

In other Medpace news, President Jesse J. Geiger sold 31,707 shares of the stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total value of $14,436,197.10. Following the sale, the president directly owned 15,000 shares in the company, valued at $6,829,500. This represents a 67.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, General Counsel Stephen P. Ewald sold 16,349 shares of the stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the sale, the general counsel owned 20,343 shares in the company, valued at $9,154,350. This represents a 44.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 20.50% of the company’s stock.

Medpace Price Performance

NASDAQ MEDP opened at $465.73 on Thursday. Medpace Holdings, Inc. has a 1 year low of $294.07 and a 1 year high of $628.92. The stock has a market capitalization of $13.30 billion, a PE ratio of 29.27, a P/E/G ratio of 2.37 and a beta of 1.18. The company’s 50 day simple moving average is $456.97 and its two-hundred day simple moving average is $505.72.

Medpace (NASDAQ:MEDP – Get Free Report) last posted its earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.74 by $0.54. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The business had revenue of $706.60 million for the quarter, compared to analysts’ expectations of $697.82 million. During the same period in the prior year, the company posted $3.67 EPS. The business’s revenue for the quarter was up 26.5% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, research analysts anticipate that Medpace Holdings, Inc. will post 17.04 EPS for the current year.

Analysts Set New Price Targets

A number of analysts recently commented on MEDP shares. Weiss Ratings cut shares of Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, April 6th. Truist Financial dropped their price target on shares of Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a research note on Wednesday, February 11th. BMO Capital Markets dropped their price target on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating on the stock in a research note on Friday, April 24th. Robert W. Baird dropped their price target on shares of Medpace from $565.00 to $477.00 and set an “outperform” rating on the stock in a research note on Friday, April 24th. Finally, Jefferies Financial Group upgraded shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 price target on the stock in a research note on Friday, February 13th. Four analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $467.08.

Read Our Latest Report on Medpace

About Medpace

(Free Report)

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.